Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17281442 | 1.00 | ADRB1 (0.67) | ADRB1KCNH2PRMT6ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1803475 | 0.98 | ADRB1 (0.65) | ADRB1KCNH2PRMT6ALDH1A1MAPT | |
| SCHEMBL12991 | 0.98 | ADRB1 (0.69) | ADRB1KCNH2PRMT6ALDH1A1MAPT | |
| SCHEMBL8264176 | 0.94 | ADRB1 (0.69) | ADRB1KCNH2PRMT6ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL27827352 | 0.92 | ADRB1 (0.67) | ADRB1KCNH2PRMT6ALDH1A1MAPT | |
| SCHEMBL10373770 | 0.89 | ADRB1 (0.74) | ADRB1KCNH2ALDH1A1MAPTRAB9A | |
| SCHEMBL11103700 | 0.89 | ADRB1 (0.74) | ADRB1KCNH2ALDH1A1MAPTRAB9A | |
| SCHEMBL22944451 | 0.86 | ADRB1 (0.51) | ADRB1KCNH2PRMT6ALDH1A1MAPT | |
| Nitrogen SCHEMBL11690640 | 0.86 | ADRB1 (0.56) | ADRB1KCNH2PRMT6ALDH1A1MAPT | |
| SCHEMBL22685038 | 0.84 | ALDH1A1 (0.59) | ADRB1PRMT6ALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2123264-A1 | Heterocyclic derivatives as abnormal cannabidiols agents for lowering intraocular pressure | Allergan, Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| US-20230242504-A1 | DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | DEUTERX LLC (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2023022497-A1 | SOS1 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-02-23 | — | — | WO | disclosed |
| EP-4067355-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYME (DUB) INHIBITORS | Mission Therapeutics Limited (GB) | 2022-10-05 | — | — | EP | disclosed |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-09 | — | — | US | disclosed |
| US-11352339-B2 | 1-cyano-pyrrolidine derivatives as DUB inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-07 | — | — | US | disclosed |
| EP-3423454-B1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-25 | — | — | EP | disclosed |
| EP-3433246-B1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-04 | — | — | EP | disclosed |
| US-20220106315-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-04-07 | — | — | US | disclosed |
| US-11236092-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-20070135600-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070135600-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
| WO-2006069788-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-07-06 | — | — | WO | disclosed |
| CN-1045595-C | Process for the preparation of the intermediates used in the synthesis of 3-aminopiperidine derivatives | PFIZER (US) | 1999-10-13 | — | — | CN | disclosed |
| US-4898941-A | Process for preparing diphenylalkene derivatives | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1990-02-06 | — | — | US | disclosed |
| US-4788285-A | COLOR FORMERS IN IMAGER TRANSFERRING, CARBONLESS COPYING, THERMAL RESPONISVE MARKING | HILTON DAVID CHEMICAL CO. | 1988-11-29 | — | — | US | disclosed |
| US-4736027-A | COLOR FORMING | HILTON DAVIS CHEMICAL CO. (US) | 1988-04-05 | — | — | US | disclosed |
| EP-0257591-A2 | Process for preparing diphenylalkene derivatives | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1988-03-02 | — | — | EP | disclosed |
| US-4660060-A | COLOR-FORMING FOR TRANSFER IMAGING; XEROGRAPHY | THE HILTON-DAVIS CHEMICAL CO. (US) | 1987-04-21 | — | — | US | disclosed |
| US-4002631-A | HEAT-SENSITIVE COLOR FORMERS | HODOGAYA CHEMICAL CO., LTD. (JA) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106315-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | OTUB1, UBE2E1, RCE1 | ADRB1 3952/4885KCNH2 4595/4885PRMT6 985/4885 |
| US-20070135600-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | AP1M1, OR10J3, AP2M1 | ADRB1 2563/4885KCNH2 2996/4885PRMT6 111/4885 |
| US-20230242504-A1 | DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | EGLN3, HPGDS, EGLN2 | ADRB1 3188/4885KCNH2 2181/4885PRMT6 1410/4885 |
| US-11352339-B2 | 1-cyano-pyrrolidine derivatives as DUB inhibitors | USP30, USP28, USP1 | ADRB1 2263/4885KCNH2 3144/4885PRMT6 565/4885 |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | USP30, USP28, USP1 | ADRB1 2263/4885KCNH2 3144/4885PRMT6 565/4885 |
| US-11236092-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | OTUB1, UBE2E1, RCE1 | ADRB1 3952/4885KCNH2 4595/4885PRMT6 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.